drugset
drugset / Trial / NCT05921591

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

NCT05921591 ↗

Phase 1 Completed 24 enrolled Revolo Biotherapeutics
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this clinical study is to assess the safety, tolerability and pharmacokinetics of repeat doses of IRL201104 given to healthy volunteers.

Timeline

Start
2023-05-26
Primary completion
2023-09-12
Completion
2023-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject IRL201104 Protein / enzyme biologic — Intravenous

Indications

No indication recorded.